Candel Therapeutics (CADL) EBITDA Margin (2020 - 2022)
Candel Therapeutics recorded quarterly EBITDA Margin of 26132.26% in Q4 2022, up 8.78% quarter-over-quarter from 28648.39% in Q3 2022, and down 5273226.0% year-over-year from N/an in Q4 2021.
Candel Therapeutics' EBITDA Margin history runs 3 years deep, the most recent figure standing at 26132.26% for Q4 2022.
- In Q4 2022, EBITDA Margin fell 5273226.0% year-over-year to 26132.26%; the TTM figure through Dec 2022 stood at 28000.81% (up 866889.0% YoY), while the FY2022 annual figure was 27777.6%, up 834640.0% from the prior year.
- EBITDA Margin came in at 26132.26% for Q4 2022 at Candel Therapeutics, up from 28648.39% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 26600.0% in Q4 2021 to a low of 55096.77% in Q2 2021.
- A 3-year average of 23468.91% and a median of 28235.48% in 2022 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin surged 6056129 bps in 2021 and sank 5273226 bps in 2022, its largest moves.
- Candel Therapeutics' EBITDA Margin stood at 33961.29% in 2020, then surged by 178 bps to 26600.0% in 2021, then slumped by 198 bps to 26132.26% in 2022.
- According to Business Quant data, EBITDA Margin over the past three periods registered 26132.26%, 28648.39%, and 28235.48% for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -26,132.26% |
| Sep 30, 2022 | -28,648.39% |
| Jun 30, 2022 | -28,235.48% |
| Mar 31, 2022 | -28,987.10% |
| Dec 31, 2021 | 26,600.00% |
| Sep 30, 2021 | -52,135.48% |
| Jun 30, 2021 | -55,096.77% |
| Mar 31, 2021 | -15,022.58% |
| Dec 31, 2020 | -33,961.29% |
| Sep 30, 2020 | -8,251.61% |
| Jun 30, 2020 | -8,287.10% |